CAS 83480-29-9|Voglibose

Introduction：Basic information about CAS 83480-29-9|Voglibose, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Voglibose BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Articles35
6. Synonyms

Common Name	Voglibose
CAS Number	83480-29-9	Molecular Weight	267.276
Density	1.6±0.1 g/cm3	Boiling Point	601.9±55.0 °C at 760 mmHg
Molecular Formula	C₁₀H₂₁NO₇	Melting Point	162-163ºC
MSDS	ChineseUSA	Flash Point	274.1±22.1 °C

Names

Name	Voglibose
Synonym	More Synonyms

Voglibose BiologicalActivity

Description	Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.Target: α-glucosidasesglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose [1]. Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats [2]. Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice [3].
Related Catalog	Signaling Pathways >>Others >>OthersResearch Areas >>Metabolic Disease
References	[1]. Chen, X., Y. Zheng, and Y. Shen, Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem, 2006. 13(1): p. 109-16. [2]. Ikenoue, T., et al., Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull, 1997. 20(4): p. 354-9. [3]. Moritoh, Y., K. Takeuchi, and M. Hazama, Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab, 2010. 12(3): p. 224-33.

Description

Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.Target: α-glucosidasesglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose [1]. Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats [2]. Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice [3].

Related Catalog

Signaling Pathways >>Others >>OthersResearch Areas >>Metabolic Disease

References

[1]. Chen, X., Y. Zheng, and Y. Shen, Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem, 2006. 13(1): p. 109-16.

[2]. Ikenoue, T., et al., Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull, 1997. 20(4): p. 354-9.

[3]. Moritoh, Y., K. Takeuchi, and M. Hazama, Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab, 2010. 12(3): p. 224-33.

Chemical & Physical Properties

Density	1.6±0.1 g/cm3
Boiling Point	601.9±55.0 °C at 760 mmHg
Melting Point	162-163ºC
Molecular Formula	C₁₀H₂₁NO₇
Molecular Weight	267.276
Flash Point	274.1±22.1 °C
Exact Mass	267.131805
PSA	153.64000
LogP	-2.36
Vapour Pressure	0.0±3.9 mmHg at 25°C
Index of Refraction	1.636
InChIKey	FZNCGRZWXLXZSZ-CIQUZCHMSA-N
SMILES	OCC(CO)NC1CC(O)(CO)C(O)C(O)C1O
Storage condition	Store at -20°C

Safety Information

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes	Xi: Irritant;
Risk Phrases	R20/21/22
Safety Phrases	S36/37
RIDADR	NONH for all modes of transport
RTECS	NM7524600

Articles35

Intensive glucose lowering in cardiovascular risk management - unsolved questions - .

Circ. J. 76(3) , 593-5, (2012)

Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.

Circ. J. 76(3) , 712-20, (2012)

Postprandial hyperglycemia and hyperinsulinemia have been considered as important determinants for the development of atherosclerosis. However, it remains to be elucidated whether correction of the po...

Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.

Int. J. Clin. Pharmacol. Ther. 52(11) , 1005-11, (2014)

The objective of this study was to evaluate the effects of voglibose on the pharmacokinetics of metformin.A randomized, open-label, two-way crossover study with a 7-day washout period was conducted. A...

Synonyms

Beigrace

Jumeal

Voglibose

Glustat

(1S,2S,3R,4S,5S)-5-[(1,3-Dihydroxy-2-propanyl)amino]-1-(hydroxymethyl)-1,2,3,4-cyclohexanetetrol

Voglibose (JP15/USAN)

Basen

Voglistat

3,4-Dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epiinositol

AO 128

MFCD00865496

1,2,3,4-Cyclohexanetetrol, 5-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-1-(hydroxymethyl)-, (1S,2S,3R,4S,5S)-

(1S,2S,3R,4S,5S)-5-[(1,3-Dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol

(1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol

N-(1,3-Dihydroxy-2-propyl)valiolamine

(1S,2S,3R,4S,5S)-5-[(1,3-Dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexan-1,2,3,4-tetrol

Recommended......